Gene Variants and Haplotypes Modifying Transcription Factor Binding Sites in the Human Cyclooxygenase 1 and 2 (PTGS1 and PTGS2) Genes

被引:25
|
作者
Agundez, Jose A. G. [1 ,2 ]
Gonzalez-Alvarez, David L. [3 ]
Vega-Rodriguez, Miguel A. [3 ]
Botello, Emilia [4 ]
Garcia-Martin, Elena [2 ,5 ]
机构
[1] Univ Extremadura, Dept Pharmacol, Caceres 10071, Spain
[2] AMGenomics, Caceres 10071, Spain
[3] Univ Extremadura, Dept Comp & Commun Technol, Caceres 10071, Spain
[4] Univ Extremadura, Dept Biochem & Mol Biol & Genet, Badajoz, Spain
[5] Univ Extremadura, Dept Biochem & Mol Biol, Caceres 10071, Spain
关键词
Cyclooxygenases; COX-1; COX-2; gene variants; PTGS1; PTGS2; upstream; transcription factor; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SINGLE NUCLEOTIDE POLYMORPHISMS; PROSTATE-CANCER RISK; BREAST-CANCER; PROMOTER POLYMORPHISMS; INFLAMMATORY GENES; NO ASSOCIATION; COLON-CANCER; COX-2; PHARMACOGENOMICS;
D O I
10.2174/138920021502140327180336
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cyclooxygenases (prostaglandin-endoperoxide synthases, (EC 1.14.99.1) 1 and 2 (COX-1 and COX-2)) are key enzymes with a highly functional and pharmacological relevance. Genetic variations in the corresponding genes PTGS1 and PTGS2 are related to diverse human disorders and adverse drug reactions. Although COX-2 is highly inducible, most genetic association studies have focused on coding region gene variants. The aim of this study is to analyze the genetic variants modifying transcription factor binding sites in human PTGS genes based on the combined use of bioinformatics with 1,000 genomes data and replication by next generation sequencing. Updated information on gene sequences and variants was obtained from the 1,000 genomes website and from a replication sequencing study. Of the 570 upstream PTGS1 gene variants, 43 altered binding sites, either by disrupting existing sequences or by creating new binding sites. The most relevant are the SNP rs72769722, which creates a new binding site for NFKB, and the SNPs rs73559017 and rs76403914, both disrupting binding sites for CDX1. Of the 682 upstream PTGS2 gene variants, 31 altered binding sites, the most relevant being rs689466 and rs20417, which disrupt binding sequences for MYB and E2F, respectively; rs689462 which creates a new binding site for POU3F2; and a haplotype combining the SNPs rs34984585+rs10911904, which creates a new binding site for SRY. This study provides a detailed catalog of variant and invariant transcription factor binding sites for PTGS genes and related haplotypes. This information can be useful to identify potential genetic targets for studies related to COX enzymes.
引用
收藏
页码:182 / 195
页数:14
相关论文
共 50 条
  • [31] Association of a promoter variant in the inducible cyclooxygenase-2 gene (PTGS2) with type 2 diabetes mellitus in Pima Indians
    Konheim, YL
    Wolford, JK
    HUMAN GENETICS, 2003, 113 (05) : 377 - 381
  • [32] Expression of Ptgs2 and Tgfb1 Genes in Rat Cartilage Cells of the Knee under Conditions of Osteoarthritis
    Dranitsina, A. S.
    Dvorshchenko, K. O.
    Korotkiy, A. G.
    Grebinyk, D. M.
    Ostapchenko, L. I.
    CYTOLOGY AND GENETICS, 2018, 52 (03) : 192 - 197
  • [33] Expression of Ptgs2 and Tgfb1 Genes in Rat Cartilage Cells of the Knee under Conditions of Osteoarthritis
    A. S. Dranitsina
    K. O. Dvorshchenko
    A. G. Korotkiy
    D. M. Grebinyk
    L. I. Ostapchenko
    Cytology and Genetics, 2018, 52 : 192 - 197
  • [34] Verification of ferroptosis and pyroptosis and identification of PTGS2 as the hub gene in human coronary artery atherosclerosis
    Zhou, Yaqing
    Zhou, Hanxiao
    Hua, Lei
    Hou, Can
    Jia, Qiaowei
    Chen, Jiaxin
    Zhang, Sheng
    Wang, Yanjun
    He, Shu
    Jia, Enzhi
    FREE RADICAL BIOLOGY AND MEDICINE, 2021, 171 : 55 - 68
  • [35] A New Molecular Variant in the PTGS1 Gene That Abrogates Generation of Thromboxane A2 Synthesis and Associates with Platelet Dysfunction and Bleeding
    Palma-Barqueros, Veronica
    Chan, Melissa
    Crescente, Marilena
    Maria Bastida, Jose
    Almarza, Elena
    Suarez Varela, Sara
    Mesa-Nunez, Cristina
    Casas-Aviles, Ignacio
    Bohdan, Natalia
    Ruiz-Pividal, Jf
    Padilla, Jose
    Revilla Calvo, Nuria
    Marin-Quilez, A.
    Martin Izquierdo, Marta
    Benito, Rocio
    Vicente, Vicente
    Bueren, Juan A.
    Maria Hernandez-Rivas, Jesus
    Ramon Gonzalez-Porras, Jose
    Edin, M. L.
    Zelding, D. C.
    Warner, Tim
    Rivera, Jose
    Luisa Lozano, Maria
    BLOOD, 2019, 134
  • [36] A common promoter variant of the gene encoding cyclooxygenase-1 (PTGS1) is related to decreased incidence of myocardial infarction in patients with coronary artery disease
    Licis, Normunds
    Krivmane, Baiba
    Latkovskis, Gustavs
    Erglis, Andrejs
    THROMBOSIS RESEARCH, 2011, 127 (06) : 600 - 602
  • [37] Ptgs2 activation by endotoxin mediates the decrease in Igf1, but not in Igfbp3, gene expression in the liver
    Martin, A. I.
    Lopez-Menduina, M.
    Castillero, E.
    Granado, M.
    Villanua, M. A.
    Lopez-Calderon, A.
    JOURNAL OF ENDOCRINOLOGY, 2008, 198 (02) : 385 - 394
  • [38] Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation
    Lira, M. Gomez
    Mazzola, S.
    Tessari, G.
    Malerba, G.
    Ortombina, M.
    Naldi, L.
    Remuzzi, G.
    Boschiero, L.
    Forni, A.
    Rugiu, C.
    Piaserico, S.
    Girolomoni, G.
    Turco, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2007, 157 (01) : 49 - 57
  • [39] ASSIGNMENT OF THE HUMAN PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE-2 (PTGS2) GENE TO 1Q25 BY FLUORESCENCE IN-SITU HYBRIDIZATION
    TAY, A
    SQUIRE, JA
    GOLDBERG, H
    SKORECKI, K
    GENOMICS, 1994, 23 (03) : 718 - 719
  • [40] Prostaglandin-endoperoxide synthase (PTGS2) and Defensin beta 1 (DEFB1) gene polymorphisms are not associated with periodontitis in Malays
    Jagender Singh, Jasmin Kaur
    Vaithilingam, Rathna Devi
    Ng, Ching Ching
    Baharuddin, Nor Adinar
    Hasnur Safii, Syarida
    Rahman, Mohammad Tariqur
    MALAYSIAN JOURNAL OF PATHOLOGY, 2021, 43 (03) : 425 - 434